CA-HALIO
HALIO, designer of the world’s fastest, most beautiful, eco-friendly, and technologically advanced electrochromic (smart) glass, and SKC Ltd., a leading company in the ESG Materials Solution industry based in South Korea, today announced that HALIO has raised up to $70M in funding from SKC to further market and develop the industry’s next generation of smart glass technology, focusing on energy savings, environmental impact, and creating beautiful facades, while enabling occupant wellness and comfort.
“This investment is expected to further expand our ESG strategy,” said SKC’s Vice President Junghwan Shin. “We strongly believe that HALIO has the most advanced smart glass technology that will significantly impact global energy savings and our environment,” emphasized Shin.
In conjunction with the funding announcement, HALIO also announced the appointment of Doug Schendt as the company's new CEO, replacing Bruce Sohn, who has served as CEO since 2020. Sohn is retiring after successfully leading the company through this latest milestone.
"I'm thrilled to take on this new role and lead HALIO into its next phase of growth," said Schendt. "Having previously led our Asia operations, I'm excited to now head HALIO globally. Bruce's vision and leadership have positioned us well, and I look forward to building on that strong foundation."
HALIO Smart Glass enables architects to design beautiful and elegant facades, supporting building owners’ pursuit of providing occupants with the most comfortable, productive, and healthy interior environments. HALIO’s Sky Camera, tint algorithms, and control automation, coupled with the industry’s fastest switching speed (within seconds), make HALIO the only smart glass solution that truly optimizes daylight control and solar heat gain management in real-time.
HALIO's smart glass technology reduces a building's operational energy use by up to 22%. It decreases peak demand by 25%, which is vital in balancing overstressed power grids (Red Car Analytics - Energy Efficiency Analysis of HALIO, Nov 2019). With countries now targeting buildings as major energy users, regulations increasingly require more efficient facades. Additionally, new incentives like the U.S. Investment Tax Credit reward owners for adding energy-saving solutions like HALIO Smart Glass.
"This new capital enables us to accelerate innovation in our smart glass technology as well as expand our reach in key markets like Asia, Europe, and the Middle East," added Sohn. "This is an incredibly exciting time for HALIO. I'm proud of what we've accomplished and am confident that with Doug as CEO, the company is in great hands to continue our mission and bring our products to customers globally."
About HALIO
HALIO Smart Glass is the world’s fastest and most advanced electrochromic (smart glass) technology, enabling maximum control of daylight while optimizing energy savings by reducing solar heat gain and minimizing glare. Powered by HALIO windows and skylights are available directly from the HALIO and third-party fabricators, including Viracon and GLASSBEL, with various glass coatings and configurations. Beautiful buildings deserve beautiful facades. Find out more what HALIO can do for your next building project at www.halioinc.com.
About SKC
For the past 40 years, SKC has focused on developing materials to create a better world, positioning today as a ‘Materials Solution Company’. SKC has recently reorganized its business portfolio, centering around rechargeable batteries, semiconductors, and eco-friendly materials. Our goal is to provide new values to customers with state-of-the-art technology and earn support and trust from both customers and society, with the vision of becoming a ‘Global Major ESG Eco-Friendly Materials Solution Company’. SKC will continue to make ceaseless challenge and innovation. Learn more: http://www.skc.co.kr/eng/main/index.do
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116891065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom